CFIA
IBER

Cantor Fitzgerald Investment Advisors’s Ibere Pharmaceuticals IBER Stock Holding History

Cantor Fitzgerald Investment Advisors’s Portfolio IBER Stock Details IBER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.1M Hold
112,050
– – 0.05% 186
2021
Q4 		$1.09M Buy
+112,050
New +$1.09M 0.07% 190

Other funds holding IBER

Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return

Cantor Fitzgerald Investment Advisors's IBER Position: Q1 2022 in Review

Cantor Fitzgerald Investment Advisors held its Ibere Pharmaceuticals (IBER) position steady in Q1 2022 at 112,050 shares worth $1.1M. The position accounts for 0.05% of the portfolio, ranked #186.

Cantor Fitzgerald Investment Advisors first reported a position in IBER in Q4 2021 and has held it in 2 quarters since. 48 funds tracked by Wall St. Rank hold IBER as of Q1 2022.

  • Cantor Fitzgerald Investment Advisors held 112,050 shares of Ibere Pharmaceuticals worth $1.1M as of Q1 2022.
  • Cantor Fitzgerald Investment Advisors left its Ibere Pharmaceuticals share count unchanged in Q1 2022.
  • Ibere Pharmaceuticals made up 0.05% of Cantor Fitzgerald Investment Advisors's portfolio in Q1 2022, its #186 holding.
  • Cantor Fitzgerald Investment Advisors first reported a position in Ibere Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • 48 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2022.

Based on Cantor Fitzgerald Investment Advisors's 13F filing for Q1 2022, filed 13 Apr 2022.